Therapeutics News and Research

RSS

Azaya Therapeutics commences ATI-0918 bioequivalence study in ovarian cancer

Azaya Therapeutics, Inc. today announced the initiation of a bioequivalence study of ATI-0918 in patients with ovarian cancer.

25 Oct 2012

Simple-to-use risk score can identify low-risk STEMI patients for early discharge

A simple-to-use risk score can identify low-risk patients following a severe heart attack (STEMI) and may provide an opportunity to employ early discharge strategies to reduce length of hospital stay and save hospital costs without compromising the safety of the patient, based on a study presented by the Minneapolis Heart Institute Foundation on Oct. 23 at the 2012 Transcatheter Cardiovascular Therapeutics (TCT) conference.

24 Oct 2012

TSRI scientists to study structural rules that govern nuclear receptors

A consortium of scientists from both campuses of The Scripps Research Institute (TSRI) has been awarded $2.7 million from the National Institute of General Medical Sciences of the National Institutes of Health to study the structural rules that govern a large superfamily of proteins that help regulate critical functions such as reproduction, development and metabolism.

24 Oct 2012

Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

Alnylam Pharmaceuticals, Inc. and Genzyme, a Sanofi company, announced today that they have formed an exclusive alliance to develop and commercialize RNAi therapeutics targeting transthyretin (TTR) for the treatment of transthyretin-mediated amyloidosis (ATTR) in Japan and other Asia-Pacific countries.

23 Oct 2012

Combining distal protection devices with nicardipine improves post-PCI outcomes

Researchers at Thomas Jefferson University Hospital have shown that combining distal protection devices with the prophylactic use of the drug nicardipine is more effective at preventing life-threatening complications following a percutaneous coronary intervention (PCI) (angioplasty, stenting) on patients who have undergone previous bypass surgery than distal protection devices alone.

23 Oct 2012

New data on Posiphen for Alzheimer's disease treatment to be presented at Biotech Symposium

QR Pharma, Inc., a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative disorders, announced today that Dr. Maria Maccecchini, CEO, will be presenting new data on its lead compound "Posiphen® Recovers Memory, Learning and Brain Function in Alzheimer Transgenic Mice" at the 12th Annual Biotech Symposium, taking place October 22, 2012 in Philadelphia, PA.

22 Oct 2012

Potential biomarker diagnostic test for pre-eclampsia

Collaborators at Cottage Health System and University of California, Santa Barbara (UCSB) have identified biomarkers that may yield a revolutionary diagnostic test for pre-eclampsia, a complex and potentially life-threatening hypertensive condition affecting 5% of pregnancies worldwide.

22 Oct 2012

MID commences treatment in Permaseal cardiac access and closure technology clinical trial

Micro Interventional Devices, Inc., an emerging cardiovascular medical device company, announced today that the first patient has been treated using its self-sealing, cardiac access and closure technology, Permaseal. The patient is the first to be enrolled in the company's STASIS clinical trial that has commenced in Europe.

22 Oct 2012

PLoS ONE publishes review of AntiViral-HyperActivation Limiting Therapeutics clinical trial

ViroStatics, a private Italian/American biopharmaceutical company developing novel therapeutics for viral and other chronic diseases, announced that a review of the first human clinical trial to test a new class of anti-HIV medications known as AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs) has been published in the peer-reviewed journal PLoS ONE.

22 Oct 2012

EvaluatePharma's Tracking Drugs@FDA provides regulatory approval analysis

EvaluatePharma, the premier source for life science sector analysis and consensus forecasts, today launched a new service enhancement, Tracking Drugs@FDA, which gives clients access to the entire universe of approved FDA drugs and the related FDA document library as well as FDA Orange Book patent data - all fully integrated into the industry-leading EvaluatePharma platform and analytical tools.

22 Oct 2012

University of Kentucky to host Makenna Foundation Symposium on Pediatric Pulmonary Disease

The University of Kentucky is hosting the first annual Makenna Foundation Symposium on Pediatric Pulmonary Disease next Friday and Saturday.

20 Oct 2012

Childhood poverty, demographics associated with DNA methylation patterns

A University of British Columbia and Centre for Molecular Medicine and Therapeutics (CMMT) study has revealed that childhood poverty, stress as an adult, and demographics such as age, sex and ethnicity, all leave an imprint on a person's genes. And, that this imprint could play a role in our immune response.

20 Oct 2012

Minnelide gives new hope for patients with pancreatic cancer

A new drug created at the University of Minnesota may hold the answer to defeating pancreatic cancer, according to results published today in the prestigious journal Science Translational Medicine.

19 Oct 2012

NIH honors Scripps Florida postdoctoral fellow with Pathway to Independence Award

The career of Antonio (Tony) Amelio, a postdoctoral fellow in the Department of Cancer Biology at The Scripps Research Institute, has gotten a boost from the National Institutes of Health in the form of a Howard Temin Pathway to Independence Award in Cancer Research.

17 Oct 2012

BioLineRx completes pre-clinical development of BL-8020 for HCV

BioLineRx, a biopharmaceutical development company, announced today that it has successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and plans to commence a Phase I/II safety and efficacy study for BL-8020 in Europe during the first quarter of 2013.

17 Oct 2012

GAPPS announces five new projects for prevention of preterm births

Five innovative research projects aiming to prevent premature birth were announced today by the Global Alliance to Prevent Prematurity and Stillbirth (GAPPS), an initiative of Seattle Children's.

16 Oct 2012

Civitas to present CVT-301 Phase 1 study results at Parkinson's Disease Therapeutics Conference

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, announced today that the Company will make its first public presentation at the Sixth Annual Parkinson's Disease Therapeutics Conference, sponsored by The Michael J. Fox Foundation for Parkinson's Research, to be held on October 24th in New York City.

15 Oct 2012

Highlights of Mount Sinai research at Neuroscience 2012

Researchers from Mount Sinai School of Medicine are presenting important discoveries on the involvement of the immune system and dopamine cells in the onset of depression at Neuroscience 2012, the Society for Neuroscience's 42nd annual meeting on October 13 -17 in New Orleans, and are available for interviews.

15 Oct 2012

Contraceptive patch suppresses ovulation in obese, nonobese women

Use of a novel transdermal contraceptive patch suppresses ovulation in obese and nonobese women, research shows.

12 Oct 2012

Downregulated protein could be revascularization target in critical limb ischemia

Levels of calcium-sensor protein, S100A1, are downregulated in patients with critical limb ischemia, say researchers who believe the protein could be a potential therapeutic target to promote revascularization.

12 Oct 2012

Therapeutics News and Research

Azaya Therapeutics commences ATI-0918 bioequivalence study in ovarian cancer

Simple-to-use risk score can identify low-risk STEMI patients for early discharge

TSRI scientists to study structural rules that govern nuclear receptors

Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

Combining distal protection devices with nicardipine improves post-PCI outcomes

New data on Posiphen for Alzheimer's disease treatment to be presented at Biotech Symposium

Potential biomarker diagnostic test for pre-eclampsia

MID commences treatment in Permaseal cardiac access and closure technology clinical trial

PLoS ONE publishes review of AntiViral-HyperActivation Limiting Therapeutics clinical trial

EvaluatePharma's Tracking Drugs@FDA provides regulatory approval analysis

University of Kentucky to host Makenna Foundation Symposium on Pediatric Pulmonary Disease

Childhood poverty, demographics associated with DNA methylation patterns

Minnelide gives new hope for patients with pancreatic cancer

NIH honors Scripps Florida postdoctoral fellow with Pathway to Independence Award

BioLineRx completes pre-clinical development of BL-8020 for HCV

GAPPS announces five new projects for prevention of preterm births

Civitas to present CVT-301 Phase 1 study results at Parkinson's Disease Therapeutics Conference

Highlights of Mount Sinai research at Neuroscience 2012

Contraceptive patch suppresses ovulation in obese, nonobese women

Downregulated protein could be revascularization target in critical limb ischemia

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News